137 related articles for article (PubMed ID: 24486846)
21. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
22. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
[TBL] [Abstract][Full Text] [Related]
23. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
24. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
25. Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma.
Ouvrier MJ; Diologent B; Edet-Sanson A; Callonnec F; Hitzel A; Pesquet AS; Hapdey S; Modzelewski R; Thillays M; Menard JF; Jardin F; Tilly H; Vera P
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):324-33. PubMed ID: 21532544
[TBL] [Abstract][Full Text] [Related]
26. How much intravenous contrast is needed in FDG-PET/CT?
Strobel K; Thuerl CM; Hany TF
Nuklearmedizin; 2005; 44 Suppl 1():S32-7. PubMed ID: 16395976
[TBL] [Abstract][Full Text] [Related]
27. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
28. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
Hutchings M; Loft A; Hansen M; Berthelsen AK; Specht L
Eur J Haematol; 2007 Mar; 78(3):206-12. PubMed ID: 17253974
[TBL] [Abstract][Full Text] [Related]
30. Performance of 18F-FDG PET/contrast-enhanced CT in the staging of squamous cell carcinoma of the oral cavity and oropharynx.
Krabbe CA; Balink H; Roodenburg JL; Dol J; de Visscher JG
Int J Oral Maxillofac Surg; 2011 Nov; 40(11):1263-70. PubMed ID: 21824748
[TBL] [Abstract][Full Text] [Related]
31. Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy Hi Art machine: final results of the VortigERN study.
Chatterjee S; Frew J; Mott J; McCallum H; Stevenson P; Maxwell R; Wilsdon J; Kelly CG
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e173-9. PubMed ID: 23079100
[TBL] [Abstract][Full Text] [Related]
32. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma.
Bednaruk-Młyński E; Pieńkowska J; Skórzak A; Małkowski B; Kulikowski W; Subocz E; Dzietczenia J; Zalewska M; Leśniewski-Kmak K; Zaucha R; Wróbel T; Zaucha JM
Leuk Lymphoma; 2015 Feb; 56(2):377-82. PubMed ID: 24794802
[TBL] [Abstract][Full Text] [Related]
33. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
[TBL] [Abstract][Full Text] [Related]
34. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
37. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
[TBL] [Abstract][Full Text] [Related]
38. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT.
Jeong HS; Baek CH; Son YI; Choi JY; Kim HJ; Ko YH; Chung JH; Baek HJ
Clin Endocrinol (Oxf); 2006 Sep; 65(3):402-7. PubMed ID: 16918964
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma.
Rauf MS; Khan ZA; Zahir MN; Al-Sweedan S; Al-Kofide A; Alharthy H; Almugbel FA; Osmani A; Elhassan TAM; Khafaga Y; Maghfoor I; Akhtar S
Nucl Med Commun; 2021 Aug; 42(8):899-906. PubMed ID: 33852535
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]